Literature DB >> 36260949

Influence of nitric oxide signaling mechanisms in cancer.

R Ramírez-Patiño1, G Avalos-Navarro1, L E Figuera2,3, J J Varela-Hernández1, L A Bautista-Herrera4, J F Muñoz-Valle5, M P Gallegos-Arreola2.   

Abstract

Nitric oxide (NO) is a molecule with multiple biological functions that is involved in various pathophysiological processes such as neurotransmission and blood vessel relaxation as well as the endocrine system, immune system, growth factors, and cancer. However, in the carcinogenesis process, it has a dual behavior; at low doses, NO regulates homeostatic functions, while at high concentrations, it promotes tissue damage or acts as an agent for immune defense against microorganisms. Thus, its participation in the carcinogenic process is controversial. Cancer is a multifactorial disease that presents complex behavior. A better understanding of the molecular mechanisms associated with the initiation, promotion, and progression of neoplastic processes is required. Some hypotheses have been proposed regarding the influence of NO in activating oncogenic pathways that trigger carcinogenic processes, because NO might regulate some signaling pathways thought to promote cancer development and more aggressive tumor growth. Additionally, NO inhibits apoptosis of tumor cells, together with the deregulation of proteins that are involved in tissue homeostasis, promoting spreading to other organs and initiating metastatic processes. This paper describes the signaling pathways that are associated with cancer, and how the concentration of NO can serve a beneficial or pathological function in the initiation and promotion of neoplastic events.

Entities:  

Keywords:  Cancer; angiogenesis; homeostasis; metastasis; nitric oxide; signaling mechanisms

Mesh:

Substances:

Year:  2022        PMID: 36260949      PMCID: PMC9585559          DOI: 10.1177/03946320221135454

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.298


  90 in total

Review 1.  Interaction of p53 with prolyl isomerases: Healthy and unhealthy relationships.

Authors:  Fiamma Mantovani; Alessandro Zannini; Alessandra Rustighi; Giannino Del Sal
Journal:  Biochim Biophys Acta       Date:  2015-01-29

2.  Selective growth inhibition of human breast cancer cells by graviola fruit extract in vitro and in vivo involving downregulation of EGFR expression.

Authors:  Yumin Dai; Shelly Hogan; Eva M Schmelz; Young H Ju; Corene Canning; Kequan Zhou
Journal:  Nutr Cancer       Date:  2011-06-22       Impact factor: 2.900

Review 3.  The Tumor Microenvironment Innately Modulates Cancer Progression.

Authors:  Dominique C Hinshaw; Lalita A Shevde
Journal:  Cancer Res       Date:  2019-07-26       Impact factor: 12.701

4.  Suppression of apoptosis by nitric oxide via inhibition of interleukin-1beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases.

Authors:  S Dimmeler; J Haendeler; M Nehls; A M Zeiher
Journal:  J Exp Med       Date:  1997-02-17       Impact factor: 14.307

5.  Regulation of nitric oxide and bcl-2 expression by shear stress in human osteoarthritic chondrocytes in vitro.

Authors:  Mel S Lee; Michael C D Trindade; Takashi Ikenoue; Stuart B Goodman; David J Schurman; Robert Lane Smith
Journal:  J Cell Biochem       Date:  2003-09-01       Impact factor: 4.429

Review 6.  The role of nitric oxide in cancer.

Authors:  Weiming Xu; Li Zhi Liu; Marilena Loizidou; Mohamed Ahmed; Ian G Charles
Journal:  Cell Res       Date:  2002-12       Impact factor: 25.617

7.  Human papillomavirus type 16 E6* induces oxidative stress and DNA damage.

Authors:  Vonetta M Williams; Maria Filippova; Valery Filippov; Kimberly J Payne; Penelope Duerksen-Hughes
Journal:  J Virol       Date:  2014-04-02       Impact factor: 5.103

8.  Nitric oxide inhibits autophagy and promotes apoptosis in hepatocellular carcinoma.

Authors:  XiaoGang Zhang; Li Jin; Zhen Tian; Jing Wang; Yuan Yang; JinFeng Liu; Yi Chen; ChunHua Hu; TianYan Chen; YingRen Zhao; YingLi He
Journal:  Cancer Sci       Date:  2019-02-16       Impact factor: 6.716

Review 9.  Controlled Delivery of Nitric Oxide for Cancer Therapy.

Authors:  Houman Alimoradi; Khaled Greish; Allan B Gamble; Gregory I Giles
Journal:  Pharm Nanotechnol       Date:  2019

10.  Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.

Authors:  Sarina A Piha-Paul; Jennifer J Wheler; Siqing Fu; Charles Levenback; Karen Lu; Gerald S Falchook; Aung Naing; David S Hong; Apostolia M Tsimberidou; Razelle Kurzrock
Journal:  Oncotarget       Date:  2014-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.